MoonLake Immunotherapeutics
sonelokimab
hidradenitis suppurativa
Countdown
146days
FDA decision · ~ Nov 30, 2026 estimated
What's at stake
The FDA's approval decision on sonelokimab for hidradenitis suppurativa is due ~ Nov 30, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 14h ago
“Clarity on the Prescription Drug User Fee Act (PDUFA) date is currently expected by the end of November 2026.”